skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

US FDA Commissioner


US FDA will propose a new rule that will blend its Quality System Regulation with international quality systems standard ISO 13485, agency Commissioner Scott Gottlieb wrote in a May 9 blog post.

"As part of our efforts to continue to ensure efficiency of existing regulations, we will be taking another step to modernize medical device regulation by proposing a new regulation to replace certain aspects of existing Quality System regulations with specifications of an international consensus standard for medical device manufacturers (ISO)," Gottlieb wrote.


The new "rule, if finalized, will harmonize domestic and international requirements, and modernize the regulation," FDA head Scott Gottlieb wrote.


ISO is the  International Organization for Standardization; device-makers use its  ISO 13485 to ensure quality systems compliance with regulators in a variety of countries, including Canada, Japan, Australia and the 28 member states of the European Union.

Gottlieb also wrote that the new "rule, if finalized, will harmonize domestic and international requirements, and modernize the regulation to make it more efficient for manufacturers of medical devices seeking to sell their products globally, while also continuing to ensure they adhere to high, internationally accepted quality systems."

FDA also added the redo of the Quality System Regulation to the agency's official regulatory agenda.

ISO 13485 was last revised in 2016; manufacturers that use the standard have until March 1, 2019, to become fully certified to the latest version or risk enforcement action.

There were rumblings of late in industry that FDA would swap out the QSR –21 CFR Part 820– with ISO 13485. And, on May 3 at MedCon 2018 in Cincinnati, Sean Boyd, deputy director for regulatory affairs for the Office of Compliance within FDA's Center for Devices and Radiological Health, confirmed that the rumors were true– that the agency was indeed considering how it could "better converge and move toward the use of ISO 13485 potentially in lieu of" the QSR. (Also see "Bye-Bye QSR? FDA May Swap Its Quality System Regulation For ISO 13485 'In The Coming Years,' Official Says" - Medtech Insight, 4 May, 2018.)

Gottlieb's post, however, suggests that the agency will be cherry-picking parts from the standard and the QSR to create a whole new regulation, rather than simply swapping the two out.

Regardless of how it's done, it would be a long-term project for the agency, Kim Trautman, executive VP of medical device international services at NSF International, toldMedtechInsightin a May 2 interview at MedCon. (Also see "NSF's Trautman Talks MDSAP, Swapping FDA's QSR For ISO 13485, Regulatory Convergence, EU's MDR & IVDR, And More" - Medtech Insight, 9 May, 2018.)

"It doesn't matter what the changes are. The same rulemaking promulgation practices need to be followed as dictated for all federal agencies," she said. That includes scheduling public comment periods and collecting comments, and performing economic impact analyses, among other tasks.

Check out what Trautman – an ex-FDA official who wrote the Quality System Regulation in the 1990s – had to say about FDA's plan to change its QSR in the podcast below, beginning at the17:26 mark:


Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    The Rise of Digital Tools eBook

    Explore the how digital technologies are being used to address the disruption of clinical trials for drugs and medical technology caused by COVID-19. Stay current with insights from industry leaders, information on guidance and regulation, and an examination of how the challenges of this global crisis and the industry’s response to it may soon usher in a new era in worldwide healthcare.

    Topics Coronavirus

  • HBW Insight: Health, Beauty and Wellness, Generics Bulletin,...

    Pharma Intelligence Launches Alexa Skill

    Keep up with topics you care about in Pharma and Medtech with the new Alexa Skill from Informa Pharma Intelligence. Now you can listen to our podcasts on subjects you choose, right from your Alexa smartphone app!

    Topics $name $name $name

  • Medtech Insight: global medical technology news & analysis

    Refined FDA Analysis Report Finds 2 Fewer Deaths Linked To Essure

    By Sue Darcey 17 Sep 2020

    In a 15 September update of adverse events from Bayer’s now-defunct Essure birth control device, the US agency tallies patients’...


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: